Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL27033104 | 1.00 | TSHR (0.69) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL1006745 | 1.00 | TSHR (0.69) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL27033077 | 1.00 | TSHR (0.69) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL711677 | 1.00 | TSHR (0.69) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL3437057 | 1.00 | TSHR (0.69) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL1449856 | 1.00 | TSHR (0.69) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL2854923 | 1.00 | TSHR (0.69) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL5573865 | 1.00 | TSHR (0.69) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL20541362 | 1.00 | TSHR (0.69) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL29484169 | 0.98 | TSHR (0.71) | TSHRALDH1A1CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459900-B2 | Compounds for treating conditions related to oxidative stress | GIRI RAJAN SHOBHANATH (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250092078-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | DECIDUOUS THERAPEUTICS, INC. (US) | 2025-03-20 | — | — | US | disclosed |
| US-20240262794-A1 | COMPOUNDS FOR TREATING CONDITIONS RELATED TO OXIDATIVE STRESS | GIRI RAJAN SHOBHANATH (US) | 2024-08-08 | — | — | US | disclosed |
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240025936-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| EP-4304583-A1 | COMPOUNDS FOR TREATING CONDITIONS RELATED TO OXIDATIVE STRESS | Giri, Rajan, Shobhanath (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-4301374-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | Deciduous Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117222414-A | Compounds for activating constant natural killer T-cells and methods for eliminating inflammatory senescent cells | 脱落性治疗公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-116669704-A | Compounds for the treatment of oxidative stress related disorders | 拉詹·绍巴纳特·吉里 | 2023-08-29 | — | — | CN | disclosed |
| US-11560395-B2 | Azithromycin derivatives containing a phosphonium ion as anticancer agents | RISING TIDE FOUND (CH) | 2023-01-24 | — | — | US | disclosed |
| US-5760259-A | MYRISTIC ACID DERIVATIVES CAPABLE OF INHIBITING BIOSYNTHESIS OF PARASITE'S ANCHORING GROUP | WASHINGTON UNIVERSITY (US) | 1998-06-02 | — | — | US | disclosed |
| US-5747537-A | Method of inhibiting parasitic activity | WASHINGTON UNIVERSITY (US) | 1998-05-05 | — | — | US | disclosed |
| US-5021414-A | Antiestrogen | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-06-04 | — | — | US | disclosed |
| US-4904661-A | ANTIESTROGENS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-02-27 | — | — | US | disclosed |
| EP-0138504-B1 | STEROID DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-07-20 | — | — | EP | disclosed |
| US-4732912-A | ANTIESTROGENS, ANTITUMOR AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-03-22 | — | — | US | disclosed |
| EP-0124369-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-06-24 | — | — | EP | disclosed |
| US-4659516-A | ANTIESTROGENS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-04-21 | — | — | US | disclosed |
| EP-0138504-A2 | Steroid derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-04-24 | — | — | EP | disclosed |
| EP-0124369-A1 | Phenol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | IL2, IL4, PBK | TSHR 3328/4885ALDH1A1 1785/4885CYP1A2 3917/4885 |
| US-12459900-B2 | Compounds for treating conditions related to oxidative stress | CYP11B1, CYP11B2, NFE2L2 | TSHR 1263/4885ALDH1A1 1300/4885CYP1A2 276/4885 |
| US-20240025936-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | IL2, PBK, IL4 | TSHR 3553/4885ALDH1A1 1217/4885CYP1A2 3908/4885 |
| US-11560395-B2 | Azithromycin derivatives containing a phosphonium ion as anticancer agents | NUP205, PHPT1, PHOSPHO1 | TSHR 3313/4885ALDH1A1 4622/4885CYP1A2 4605/4885 |
| US-20250092078-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | IL2, PBK, IL4 | TSHR 3503/4885ALDH1A1 1215/4885CYP1A2 3832/4885 |
| US-20240262794-A1 | COMPOUNDS FOR TREATING CONDITIONS RELATED TO OXIDATIVE STRESS | CYP11B1, CYP11B2, NFE2L2 | TSHR 1263/4885ALDH1A1 1300/4885CYP1A2 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.